Global Parkinson's Disease Market Analysis 2016 - Forecast to 2022

  • ID: 3845824
  • Report
  • Region: Global
  • 122 pages
  • Hoovers Research
1 of 3
This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Parkinson’s Disease". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:
- Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
- Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping mapping the key common trends
- Company profiling covering the financials, recent activities and the future strategies
- Supply chain trends mapping the recent advancements
- Strategic recommendations for the new entrants
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
3.5 Pipeline Analysis

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Parkinson’s Disease Market by Therapy
5.1 Introduction
5.2 Dopamine Replacement Therapies
5.2.1 Levodopa Combination Therapy
5.2.1.1 Madopar (levodopa/benserazide)
5.2.1.2 Rytary
5.2.1.3 Sinemet (carbidopa/levodopa)
5.3 MAO-B Inhibitors
5.3.1 Azilect (rasagiline)
5.3.2 Xadago (safinamide)
5.4 Dopamine Agonists
5.4.1 Apokyn (apomorphine)
5.4.2 Neupro (rotigotine transdermal patch)
5.4.3 Requip/Requip XL (ropinirole)
5.5 Catechol-O-Methyl Transferase COMT Inhibitors
5.5.1 Stalevo/Comtan (entacapone)
5.6 Adenosine 2A Inhibitor
5.6.1 Nouriast (istradefylline)

6 Parkinson’s Disease Market by Product
6.1 Introduction
6.2 Nuplazid (pimavanserin)
6.3 Opicapone
6.4 Nurelin (Amantadine Hydrochloride Extended-Release)
6.5 APL-130277 (apomorphine hydrochloride)
6.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate)
6.7 CVT-301 (levodopa)
6.8 Symmetrel (amantadine hydrochloride)
6.9 Dipraglurant Immediate
6.10 ND-0612L (levodopa and carbidopa)
6.11 Exelon (rivastigmine tartrate)
6.12 Nouriast (istradefylline)
6.13 Tozadenant

7 Geographical Segmentation
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 RoW
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa
7.4.4 Others

8 Vendor Landscaping
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiles
9.1 Biotie Therapies Corp.
9.1.1 Business Overview
9.1.2 SWOT Analysis
9.1.3 Financial Overview
9.1.4 Strategy
9.1.5 Key Activities
9.2 Ono Pharmaceutical Co., Ltd.
9.3 Ceregene, Inc
9.4 Domain Therapeutics S.A
9.5 Dexcel Pharma
9.6 Novartis International AG
9.7 Pfizer, Inc.
9.8 Newron Pharmaceuticals S.p.A
9.9 Cephalon, Inc
9.10 Shire Pharmaceutical Group Plc
9.11 Heptares Therapeutics Ltd
9.12 Neuropore Therapies
9.13 Sellas Life Sciences
9.14 Adamas Pharmaceuticals Inc.
9.15 UbiQ
9.16 Dainippon Sumitomo Pharma
9.17 MedGenesis Therapeutix
9.18 Lundbeck

10 Appendix
11 Disclaimer

List of Tables
Table 1 Global Parkinson’s Disease Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Parkinson’s Disease Market Analysis, by Therapy, 2013-2022 ($MN)
Table 3 Global Dopamine Replacement Therapies Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Dopamine Replacement Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 5 Global MAO-B Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 6 Global MAO-B Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 7 Global Dopamine Agonists Market Analysis, by Region, 2013-2022 ($MN)
Table 8 Global Dopamine Agonists Market Analysis, by Product, 2013-2022 ($MN)
Table 9 Global Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 10 Global Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 11 Global Adenosine 2A Inhibitor Market Analysis, by Region, 2013-2022 ($MN)
Table 12 Global Adenosine 2A Inhibitor Market Analysis, by Product, 2013-2022 ($MN)
Table 13 Global Parkinson’s Disease Market Analysis, by Product, 2013-2022 ($MN)
Table 14 Global Nuplazid (pimavanserin) Market Analysis, by Region, 2013-2022 ($MN)
Table 15 Global Nuplazid (pimavanserin) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 16 Global Opicapone Market Analysis, by Region, 2013-2022 ($MN)
Table 17 Global Opicapone Market Analysis, by Therapy, 2013-2022 ($MN)
Table 18 Global Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Region, 2013-2022 ($MN)
Table 19 Global Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 20 Global APL-130277 (apomorphine hydrochloride) Market Analysis, by Region, 2013-2022 ($MN)
Table 21 Global APL-130277 (apomorphine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 22 Global P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Region, 2013-2022 ($MN)
Table 23 Global P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 24 Global CVT-301 (levodopa) Market Analysis, by Region, 2013-2022 ($MN)
Table 25 Global CVT-301 (levodopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 26 Global Symmetrel (amantadine hydrochloride) Market Analysis, by Region, 2013-2022 ($MN)
Table 27 Global Symmetrel (amantadine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 28 Global Dipraglurant Immediate Market Analysis, by Region, 2013-2022 ($MN)
Table 29 Global Dipraglurant Immediate Market Analysis, by Therapy, 2013-2022 ($MN)
Table 30 Global ND-0612L (levodopa and carbidopa) Market Analysis, by Region, 2013-2022 ($MN)
Table 31 Global ND-0612L (levodopa and carbidopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 32 Global Exelon (rivastigmine tartrate) Market Analysis, by Region, 2013-2022 ($MN)
Table 33 Global Exelon (rivastigmine tartrate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 34 Global Nouriast (istradefylline) Market Analysis, by Region, 2013-2022 ($MN)
Table 35 Global Nouriast (istradefylline) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 36 Global Tozadenant Market Analysis, by Region, 2013-2022 ($MN)
Table 37 Global Tozadenant Market Analysis, by Therapy, 2013-2022 ($MN)
Table 38 North America Parkinson’s Disease Market Analysis, by Country, 2013-2022 ($MN)
Table 39 North America Parkinson’s Disease Market Analysis, by Therapy, 2013-2022 ($MN)
Table 40 North America Dopamine Replacement Therapies Market Analysis, by Country, 2013-2022 ($MN)
Table 41 North America Dopamine Replacement Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 42 North America MAO-B Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 43 North America MAO-B Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 44 North America Dopamine Agonists Market Analysis, by Country, 2013-2022 ($MN)
Table 45 North America Dopamine Agonists Market Analysis, by Product, 2013-2022 ($MN)
Table 46 North America Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 47 North America Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 48 North America Adenosine 2A Inhibitor Market Analysis, by Country, 2013-2022 ($MN)
Table 49 North America Adenosine 2A Inhibitor Market Analysis, by Product, 2013-2022 ($MN)
Table 50 North America Parkinson’s Disease Market Analysis, by Product, 2013-2022 ($MN)
Table 51 North America Nuplazid (pimavanserin) Market Analysis, by Country, 2013-2022 ($MN)
Table 52 North America Nuplazid (pimavanserin) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 53 North America Opicapone Market Analysis, by Country, 2013-2022 ($MN)
Table 54 North America Opicapone Market Analysis, by Therapy, 2013-2022 ($MN)
Table 55 North America Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Country, 2013-2022 ($MN)
Table 56 North America Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 57 North America APL-130277 (apomorphine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 58 North America APL-130277 (apomorphine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 59 North America P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Country, 2013-2022 ($MN)
Table 60 North America P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 61 North America CVT-301 (levodopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 62 North America CVT-301 (levodopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 63 North America Symmetrel (amantadine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 64 North America Symmetrel (amantadine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 65 North America Dipraglurant Immediate Market Analysis, by Country, 2013-2022 ($MN)
Table 66 North America Dipraglurant Immediate Market Analysis, by Therapy, 2013-2022 ($MN)
Table 67 North America ND-0612L (levodopa and carbidopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 68 North America ND-0612L (levodopa and carbidopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 69 North America Exelon (rivastigmine tartrate) Market Analysis, by Country, 2013-2022 ($MN)
Table 70 North America Exelon (rivastigmine tartrate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 71 North America Nouriast (istradefylline) Market Analysis, by Country, 2013-2022 ($MN)
Table 72 North America Nouriast (istradefylline) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 73 North America Tozadenant Market Analysis, by Country, 2013-2022 ($MN)
Table 74 North America Tozadenant Market Analysis, by Therapy, 2013-2022 ($MN)
Table 75 Europe Parkinson’s Disease Market Analysis, by Country, 2013-2022 ($MN)
Table 76 Europe Parkinson’s Disease Market Analysis, by Therapy, 2013-2022 ($MN)
Table 77 Europe Dopamine Replacement Therapies Market Analysis, by Country, 2013-2022 ($MN)
Table 78 Europe Dopamine Replacement Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 79 Europe MAO-B Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 80 Europe MAO-B Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 81 Europe Dopamine Agonists Market Analysis, by Country, 2013-2022 ($MN)
Table 82 Europe Dopamine Agonists Market Analysis, by Product, 2013-2022 ($MN)
Table 83 Europe Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 84 Europe Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 85 Europe Adenosine 2A Inhibitor Market Analysis, by Country, 2013-2022 ($MN)
Table 86 Europe Adenosine 2A Inhibitor Market Analysis, by Product, 2013-2022 ($MN)
Table 87 Europe Parkinson’s Disease Market Analysis, by Product, 2013-2022 ($MN)
Table 88 Europe Nuplazid (pimavanserin) Market Analysis, by Country, 2013-2022 ($MN)
Table 89 Europe Nuplazid (pimavanserin) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 90 Europe Opicapone Market Analysis, by Country, 2013-2022 ($MN)
Table 91 Europe Opicapone Market Analysis, by Therapy, 2013-2022 ($MN)
Table 92 Europe Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Country, 2013-2022 ($MN)
Table 93 Europe Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 94 Europe APL-130277 (apomorphine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 95 Europe APL-130277 (apomorphine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 96 Europe P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Country, 2013-2022 ($MN)
Table 97 Europe P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 98 Europe CVT-301 (levodopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 99 Europe CVT-301 (levodopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 100 Europe Symmetrel (amantadine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 101 Europe Symmetrel (amantadine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 102 Europe Dipraglurant Immediate Market Analysis, by Country, 2013-2022 ($MN)
Table 103 Europe Dipraglurant Immediate Market Analysis, by Therapy, 2013-2022 ($MN)
Table 104 Europe ND-0612L (levodopa and carbidopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 105 Europe ND-0612L (levodopa and carbidopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 106 Europe Exelon (rivastigmine tartrate) Market Analysis, by Country, 2013-2022 ($MN)
Table 107 Europe Exelon (rivastigmine tartrate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 108 Europe Nouriast (istradefylline) Market Analysis, by Country, 2013-2022 ($MN)
Table 109 Europe Nouriast (istradefylline) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 110 Europe Tozadenant Market Analysis, by Country, 2013-2022 ($MN)
Table 111 Europe Tozadenant Market Analysis, by Therapy, 2013-2022 ($MN)
Table 112 Asia Pacific Parkinson’s Disease Market Analysis, by Country, 2013-2022 ($MN)
Table 113 Asia Pacific Parkinson’s Disease Market Analysis, by Therapy, 2013-2022 ($MN)
Table 114 Asia Pacific Dopamine Replacement Therapies Market Analysis, by Country, 2013-2022 ($MN)
Table 115 Asia Pacific Dopamine Replacement Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 116 Asia Pacific MAO-B Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 117 Asia Pacific MAO-B Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 118 Asia Pacific Dopamine Agonists Market Analysis, by Country, 2013-2022 ($MN)
Table 119 Asia Pacific Dopamine Agonists Market Analysis, by Product, 2013-2022 ($MN)
Table 120 Asia Pacific Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 121 Asia Pacific Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 122 Asia Pacific Adenosine 2A Inhibitor Market Analysis, by Country, 2013-2022 ($MN)
Table 123 Asia Pacific Adenosine 2A Inhibitor Market Analysis, by Product, 2013-2022 ($MN)
Table 124 Asia Pacific Parkinson’s Disease Market Analysis, by Product, 2013-2022 ($MN)
Table 125 Asia Pacific Nuplazid (pimavanserin) Market Analysis, by Country, 2013-2022 ($MN)
Table 126 Asia Pacific Nuplazid (pimavanserin) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 127 Asia Pacific Opicapone Market Analysis, by Country, 2013-2022 ($MN)
Table 128 Asia Pacific Opicapone Market Analysis, by Therapy, 2013-2022 ($MN)
Table 129 Asia Pacific Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Country, 2013-2022 ($MN)
Table 130 Asia Pacific Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 131 Asia Pacific APL-130277 (apomorphine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 132 Asia Pacific APL-130277 (apomorphine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 133 Asia Pacific P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Country, 2013-2022 ($MN)
Table 134 Asia Pacific P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 135 Asia Pacific CVT-301 (levodopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 136 Asia Pacific CVT-301 (levodopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 137 Asia Pacific Symmetrel (amantadine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 138 Asia Pacific Symmetrel (amantadine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 139 Asia Pacific Dipraglurant Immediate Market Analysis, by Country, 2013-2022 ($MN)
Table 140 Asia Pacific Dipraglurant Immediate Market Analysis, by Therapy, 2013-2022 ($MN)
Table 141 Asia Pacific ND-0612L (levodopa and carbidopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 142 Asia Pacific ND-0612L (levodopa and carbidopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 143 Asia Pacific Exelon (rivastigmine tartrate) Market Analysis, by Country, 2013-2022 ($MN)
Table 144 Asia Pacific Exelon (rivastigmine tartrate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 145 Asia Pacific Nouriast (istradefylline) Market Analysis, by Country, 2013-2022 ($MN)
Table 146 Asia Pacific Nouriast (istradefylline) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 147 Asia Pacific Tozadenant Market Analysis, by Country, 2013-2022 ($MN)
Table 148 Asia Pacific Tozadenant Market Analysis, by Therapy, 2013-2022 ($MN)
Table 149 RoW Parkinson’s Disease Market Analysis, by Country, 2013-2022 ($MN)
Table 150 RoW Parkinson’s Disease Market Analysis, by Therapy, 2013-2022 ($MN)
Table 151 RoW Dopamine Replacement Therapies Market Analysis, by Country, 2013-2022 ($MN)
Table 152 RoW Dopamine Replacement Therapies Market Analysis, by Product, 2013-2022 ($MN)
Table 153 RoW MAO-B Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 154 RoW MAO-B Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 155 RoW Dopamine Agonists Market Analysis, by Country, 2013-2022 ($MN)
Table 156 RoW Dopamine Agonists Market Analysis, by Product, 2013-2022 ($MN)
Table 157 RoW Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Country, 2013-2022 ($MN)
Table 158 RoW Catechol-O-Methyl Transferase COMT Inhibitors Market Analysis, by Product, 2013-2022 ($MN)
Table 159 RoW Adenosine 2A Inhibitor Market Analysis, by Country, 2013-2022 ($MN)
Table 160 RoW Adenosine 2A Inhibitor Market Analysis, by Product, 2013-2022 ($MN)
Table 161 RoW Parkinson’s Disease Market Analysis, by Product, 2013-2022 ($MN)
Table 162 RoW Nuplazid (pimavanserin) Market Analysis, by Country, 2013-2022 ($MN)
Table 163 RoW Nuplazid (pimavanserin) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 164 RoW Opicapone Market Analysis, by Country, 2013-2022 ($MN)
Table 165 RoW Opicapone Market Analysis, by Therapy, 2013-2022 ($MN)
Table 166 RoW Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Country, 2013-2022 ($MN)
Table 167 RoW Nurelin (Amantadine Hydrochloride Extended-Release) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 168 RoW APL-130277 (apomorphine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 169 RoW APL-130277 (apomorphine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 170 RoW P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Country, 2013-2022 ($MN)
Table 171 RoW P2B001 (pramipexole dihydrochloride + rasagiline mesylate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 172 RoW CVT-301 (levodopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 173 RoW CVT-301 (levodopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 174 RoW Symmetrel (amantadine hydrochloride) Market Analysis, by Country, 2013-2022 ($MN)
Table 175 RoW Symmetrel (amantadine hydrochloride) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 176 RoW Dipraglurant Immediate Market Analysis, by Country, 2013-2022 ($MN)
Table 177 RoW Dipraglurant Immediate Market Analysis, by Therapy, 2013-2022 ($MN)
Table 178 RoW ND-0612L (levodopa and carbidopa) Market Analysis, by Country, 2013-2022 ($MN)
Table 179 RoW ND-0612L (levodopa and carbidopa) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 180 RoW Exelon (rivastigmine tartrate) Market Analysis, by Country, 2013-2022 ($MN)
Table 181 RoW Exelon (rivastigmine tartrate) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 182 RoW Nouriast (istradefylline) Market Analysis, by Country, 2013-2022 ($MN)
Table 183 RoW Nouriast (istradefylline) Market Analysis, by Therapy, 2013-2022 ($MN)
Table 184 RoW Tozadenant Market Analysis, by Country, 2013-2022 ($MN)
Table 185 RoW Tozadenant Market Analysis, by Therapy, 2013-2022 ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll